文献速递核素与放射性配体治疗肿瘤 PET/CT

[177Lu]Lu-PSMA-617联合或不联合ARPI治疗mCRPC的真实世界疗效

Efficacy and outcomes of [177Lu]Lu-PSMA-617 in patients with mCRPC treated with or without concurrent ARPI: a real-world single-center analysis.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2026-07-10

该单中心回顾性研究分析了2023年6月至2024年8月接受[177Lu]Lu-PSMA-617治疗的108例mCRPC患者,其中65例单药治疗、43例同期联合ARPI。两组中位OS、PSA50应答率、PSA-PFS及PSA变化均无显著差异,多因素Cox回归显示同期使用ARPI与OS无独立关联。

要点

  • 同期ARPI与单药组的中位OS(12.7 vs. 13.5个月)和PSA50应答率无显著差异
  • rPFS在ARPI组呈非显著获益趋势(10.6 vs. 9.8个月,p=0.057)
  • 多因素分析中同期ARPI与OS无独立关联(校正HR 1.29,p=0.33)

核心结论

  • 在ARPI和紫杉烷预治疗的mCRPC真实世界队列中,[177Lu]Lu-PSMA-617治疗期间同期使用ARPI与临床结局改善无独立关联。
  • 探索性结果不支持在启动放射性配体治疗时对已进展患者常规继续ARPI。

研究设计与样本

  • 单中心真实世界回顾性分析,纳入2023年6月至2024年8月常规临床实践中接受[177Lu]Lu-PSMA-617治疗的mCRPC患者108例。
  • 65例接受[177Lu]Lu-PSMA-617单药治疗,43例同期联合ARPI治疗。
  • 主要终点为总生存(OS)和PSA50应答,次要终点包括PSA-PFS、rPFS和PSA较基线变化百分比。
  • 基线特征采用Mann-Whitney U检验和卡方检验比较,生存结局采用Kaplan-Meier和Cox回归分析。

主要发现

  • 两组中位OS为12.7 vs. 13.5个月(p=0.96),PSA50应答率为51.2% vs. 52.3%(p=0.91)。
  • PSA-PFS为6.3 vs. 6.2个月(p=0.54),中位PSA较基线变化为-39.0% vs. -43.1%(p=0.24)。
  • rPFS在ARPI组呈非显著趋势(10.6 vs. 9.8个月,p=0.057)。
  • 基线特征总体均衡,ARPI组血红蛋白略高、PSA有偏低趋势。
  • 多因素Cox回归显示同期ARPI与OS无独立关联(校正HR 1.29,p=0.33)。

关键数值与推荐

  • PSA50应答定义及OS、PSA-PFS、rPFS的具体判定标准原文未报告。
  • 患者为ARPI和紫杉烷预治疗的mCRPC人群,原文未报告具体既往治疗线数。
  • 原文未报告[177Lu]Lu-PSMA-617的给药剂量与周期方案。

临床怎么用

  • 对于ARPI治疗后进展的mCRPC患者,启动[177Lu]Lu-PSMA-617时不必仅为改善生存而常规继续ARPI。
  • 是否继续ARPI应结合个体情况个体化决策,本探索性结果不构成停药或继续用药的强制性依据。

局限性

  • 单中心回顾性设计,样本量108例,存在选择偏倚与混杂可能。
  • ARPI组与单药组部分基线指标存在差异(血红蛋白略高、PSA偏低趋势)。
  • rPFS差异仅为非显著趋势(p=0.057),需更大样本验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: [177Lu]Lu-PSMA-617 was approved after the VISION trial demonstrated significant benefit in metastatic castration-resistant prostate cancer (mCRPC). This study evaluated outcomes of [177Lu]Lu-PSMA-617 with or without concurrent Androgen Receptor Pathway Inhibitors (ARPI) in a real-world setting. METHODS: We retrospectively analyzed electronic health records of mCRPC patients treated with [177Lu]Lu-PSMA-617 in routine clinical practice between June 2023 and August 2024. Primary endpoints were overall survival (OS) and PSA50 response; secondary endpoints included PSA-progression-free survival (PSA-PFS), radiographic PFS (rPFS), and percentage PSA change from baseline. Baseline characteristics were compared using Mann-Whitney U and chi-square tests. Survival outcomes were evaluated using Kaplan-Meier and Cox regression analyses. RESULTS: Among 108 patients, 65 received [177Lu]Lu-PSMA-617 monotherapy and 43 concurrent ARPI therapy. Baseline characteristics were generally well balanced, with slightly higher hemoglobin and a trend toward lower PSA in the ARPI group. No significant between-group differences were observed for median OS (12.7 vs. 13.5 months; p = 0.96), PSA50 response rate (51.2% vs. 52.3%; p = 0.91), PSA-PFS (6.3 vs. 6.2 months; p = 0.54), or median PSA change from baseline (-39.0% vs. -43.1%; p = 0.24). A non-significant trend in rPFS favored the ARPI group (10.6 vs. 9.8 months; p = 0.057). On multivariable Cox regression, concurrent ARPI use was not independently associated with OS (adjusted HR 1.29; p = 0.33). CONCLUSION: In this real-world cohort of ARPI- and taxane-pretreated mCRPC patients, concurrent ARPI use during [177Lu]Lu-PSMA-617 was not independently associated with improved clinical outcomes. These exploratory findings do not provide evidence to support routine continuation of ARPI beyond progression at the time of radioligand therapy initiation.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Rust M, Ventura D, Backhaus C, et al. Efficacy and outcomes of [177Lu]Lu-PSMA-617 in patients with mCRPC treated with or without concurrent ARPI: a real-world single-center analysis. Eur J Nucl Med Mol Imaging. 2026. PMID: 42429823. doi:10.1007/s00259-026-08060-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。